As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ramped up legal actions against its competitors. | As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ...

Two days after Monte Rosa Therapeutics Inc. signed a molecular glue degrader deal with Novartis AG, two other companies, ...

Q3 2024 Earnings Call Transcript October 29, 2024 Novartis AG beats earnings expectations. Reported EPS is $2.06, expectations were $1.96. Operator: Good morning and good afternoon, and welcome to the ...

Novartis AG ( (NVS) ) has realeased its Q3 earnings. Here is a breakdown of the information Novartis AG presented to its investors. Novartis AG ...

Basel, October 29, 2024 – Novartis announced today that Scemblix ® (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed ...

Operator Good morning and good afternoon, and welcome to the Novartis Q3 2024 results release conference call and live ...

On Tuesday, Novartis AG (NYSE:NVS) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), ...

Novartis AG’s best-selling drug and a key new cancer medicine posted disappointing sales last quarter, even as the Swiss drugmaker lifted profit guidance for a third straight quarter.

In a report released today, Richard Vosser from J.P. Morgan maintained a Hold rating on Novartis AG (NOVN – Research Report), with a ...

BASEL, Switzerland (AP) — BASEL, Switzerland (AP) — Novartis AG (NVS) on Tuesday reported third-quarter earnings of $3.19 ...

European equities fell on Tuesday after disappointing earnings from heavyweights BP Plc and Novartis AG and as traders assessed growing market risks in what is shaping up as a key week for stocks.

An old target that found new life at Monte Rosa Therapeutics Inc. has become the subject of a sizeable deal between the ...